BMY250103P53000
- 0.05
- 0.000.00%
Bristol-Myers Squibb Newsroom
Express News | Bristol-Myers Squibb Co -Preliminary Estimated Q4 Impact of Acquired in-Process Research and Development and Licensing Loss of $18 Mln
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
Bristol-Myers Squibb Options Spot-On: On January 2nd, 391.89K Contracts Were Traded, With 617.52K Open Interest
On January 2nd ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 391.89K options for the day, of which put options accounted for 1.2% of the total
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $70
Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Bristol-Myers Squibb To Go Ex-Dividend On January 3rd, 2025 With 0.62 USD Dividend Per Share
January 1st (Eastern Time) - $Bristol-Myers Squibb(BMY.US)$ is trading ex-dividend on January 3rd, 2025.Shareholders of record on January 3rd, 2025 will receive 0.62 USD dividend per share on
Brand Prescription Drugs to Rise an Average 4.5% in 2025
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Peering Into Bristol-Myers Squibb's Recent Short Interest
Pharmaceutical companies will raise the prices of over 250 drugs in the USA next year, with an increase of less than 10%.
On December 31, according to data analyzed by the healthcare research company 3 Axis Advisors, pharmaceutical companies plan to raise the prices of at least 250 brand-name drugs in the USA by early 2025, including Pfizer's COVID-19 drug Paxlovid, Bristol-Myers Squibb's therapy, and Sanofi's vaccine. Almost all of the price increases for pharmaceuticals are below 10%, with a median increase of 4.5%, consistent with last year. The prices being raised are the list prices, excluding rebates and other discounts offered to pharmacy benefit managers. In recent years, sharp criticism has arisen due to the increase in drug prices.
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Oncology Pharmaceuticals Market Research 2024-2029, Profiles of Major Players - Bristol-Myers Squibb, Merck & Co, F. Hoffmann-La Roche, Johnson & Johnson, and AstraZeneca
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
Bristol-Myers Squibb's Patent Expansion Plan May Run Into Regulator Trouble
Brain Tumor Therapeutics Global Research Business Report 2024-2030 Featuring Profiles of Market Leaders Including AstraZeneca, Bristol-Myers Squibb, DelMar Pharmaceuticals - ResearchAndMarkets.com
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $62